Back to top
more

Galectin Therapeutics (GALT)

(Delayed Data from NSDQ)

$3.59 USD

3.59
238,445

-0.06 (-1.64%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $3.54 -0.05 (-1.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

    Zacks Equity Research

    Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?

    by Zacks Equity Research

    Investors in Galectin Therapeutics (GALT) need to pay close attention to the stock based on moves in the options market lately.

      Zacks Equity Research

      Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock?

      by Zacks Equity Research

      Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

        Ekta Bagri headshot

        NASH Space in Focus as Galmed (GLMD) Posts Positive Data

        by Ekta Bagri

        Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

          Zacks Equity Research

          Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?

          by Zacks Equity Research

          Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

            Zacks Equity Research

            Galectin Therapeutics (GALT) Jumps: Stock Rises 15.1%

            by Zacks Equity Research

            Galectin Therapeutics Inc. (GALT) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.

              Zacks Equity Research

              Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options

              by Zacks Equity Research

              Investors in Galectin Therapeutics (GALT) need to pay close attention to the stock based on moves in the options market lately.

                Zacks Equity Research

                Galectin Therapeutics (GALT) in Focus: Stock Moves 6.5% Higher

                by Zacks Equity Research

                Galectin Therapeutics, Inc. (GALT) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.

                  Zacks Equity Research

                  Can The Uptrend Continue for Galectin Therapeutics (GALT)?

                  by Zacks Equity Research

                  Investors certainly have to be happy with Galectin Therapeutics Inc (GALT) and its short term performance

                    Zacks Equity Research

                    Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?

                    by Zacks Equity Research

                    Henry Schein, Inc. (HSIC) is expected to report first-quarter 2017 results on May 2, before the opening bell.

                      Zacks Equity Research

                      Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?

                      by Zacks Equity Research

                      Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.

                        Zacks Equity Research

                        Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store?

                        by Zacks Equity Research

                        Edward Lifesciences Corp. (EW) is scheduled to report first-quarter 2017 earnings results after market close on Apr 25.

                          Zacks Equity Research

                          Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings?

                          by Zacks Equity Research

                          Mead Johnson Nutrition Company (MJN) is expected to report first-quarter 2017 results on Apr 27, before the opening bell.

                            Zacks Equity Research

                            ResMed (RMD) Q3 Earnings: Disappointment in the Cards?

                            by Zacks Equity Research

                            ResMed Inc. (RMD) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.

                              Zacks Equity Research

                              IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store?

                              by Zacks Equity Research

                              IDEXX Laboratories, Inc. (IDXX) is slated to report first-quarter 2017 results on Apr 28, before the opening bell.

                                Zacks Equity Research

                                Can Illumina (ILMN) Spring a Surprise this Earnings Season?

                                by Zacks Equity Research

                                Illumina Inc. (ILMN), a leading provider of tools and integrated systems for analysis of genetic variation and function, is scheduled to report first-quarter 2017 financial results on Apr 25, after the closing bell.

                                  Zacks Equity Research

                                  Integra LifeSciences (IART) Q1 Earnings: A Beat in Store?

                                  by Zacks Equity Research

                                  We expect Integra LifeSciences Holdings Corporation (IART) to beat expectations when it reports its first-quarter 2017 results, after market close on Apr 26.

                                    Zacks Equity Research

                                    GNC Holdings (GNC) Q1 Earnings: Disappointment in Store?

                                    by Zacks Equity Research

                                    GNC Holdings, Inc. (GNC) -- a specialty retailer of health and nutrition related products -- is scheduled to report first-quarter 2017 financial results on Apr 18, before the opening bell.

                                      Zacks Equity Research

                                      Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7%

                                      by Zacks Equity Research

                                      Galectin Therapeutics, Inc. (GALT) shares rose nearly 17% in the last trading session.

                                        Zacks Equity Research

                                        Can The Uptrend Continue for Galectin Therapeutics (GALT)?

                                        by Zacks Equity Research

                                        Investors certainly have to be happy with Galectin Therapeutics Inc (GALT) and its short term performance